Fewer GI Side Effects Seen in Study of Oral LYT-100 vs Esbriet

Fewer GI Side Effects Seen in Study of Oral LYT-100 vs Esbriet

315839

Fewer GI Side Effects Seen in Study of Oral LYT-100 vs Esbriet

About half of the healthy older adults given PureTech’s anti-fibrotic therapy LYT-100 (deupirfenidone) were less likely to report gastrointestinal (GI) side effects compared with those given Esbriet (pirfenidone), according to a recent crossover study. Based on these findings, data to date from LYT-100’s clinical program and regulatory feedback, the company plans to launch a dose-ranging study evaluating six months of LYT-100 treatment in people with idiopathic pulmonary fibrosis (IPF) by June. LYT-100 is a modified version of…

You must be logged in to read/download the full post.